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Abstract
In a previous article, an algorithm for identifying therapeutic targets
in Boolean networks modeling pathological mechanisms was introduced.
In the present article, the improvements made on this algorithm, named
kali, are described. These improvements are i) the possibility to work
on asynchronous Boolean networks, ii) a finer assessment of therapeutic
targets and iii) the possibility to use multivalued logic. kali assumes that
the attractors of a dynamical system, such as a Boolean network, are as-
sociated with the phenotypes of the modeled biological system. Given
a logic-based model of pathological mechanisms, kali searches for thera-
peutic targets able to reduce the reachability of the attractors associated
with pathological phenotypes, thus reducing their likeliness. kali is illus-
trated on an example network and used on a biological case study. The
case study is a published logic-based model of bladder tumorigenesis from
which kali returns consistent results. However, like any computational
tool, kali can predict but can not replace human expertise: it is a sup-
porting tool for coping with the complexity of biological systems in the
field of drug discovery.
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1 Introduction
In a previous article, an algorithm for in silico therapeutic target discovery was
presented in its first version [1]. In the present article, the improvements made
on this algorithm, named kali, are described. The complete background was
introduced in the previous article whose some important concepts are recalled
in Appendix 1 page 22.
kali still belongs to the logic-based modeling formalism [2–4], mainly Boolean
networks [5, 6], and keeps its original goal: searching for therapeutic interven-
tions aimed at healing a supplied pathologically disturbed biological network.
Such a network is intended to model the biological mechanisms of a studied
disease and is on what kali operates. Therapeutic interventions are combina-
tions of targets, these combinations being named bullets. Targets are network
components, such as enzymes or transcription factors, and can be subjected to
inhibition or activation. This is what bullets specify: which targets and which
actions to apply on them.
The pivotal assumption on which kali is based postulates that the attrac-
tors of a dynamical system, such as a Boolean network, are associated with the
phenotypes of the modeled biological system. In other words: attractors model
phenotypes [7]. This assumption was successfully applied in several works [8–14]
and makes sense since the steady states of a dynamical system, the attractors,
should mirror the steady states of the modeled biological system, the pheno-
types.
In the mean time, various works using logical modeling with application
in therapeutic innovation were published. An example is the work of Hyunho
Chu and colleagues [15]. They built a molecular interaction network involved
in colorectal tumorigenesis and studied its dynamics, particularly its attractors
and their basins, with stochastic Boolean modeling. They highlighted what
they termed the flickering, that is the displacement of the system from one
basin to another one due to stochastic noise. They suggested that the flickering
is involved in pushing the system from a physiological state to a pathological
one during colorectal tumorigenesis.
Concerning kali, three improvements were done: i) adding the possibility to
work with asynchronous Boolean networks, ii) implementing a finer assessment
of therapeutic targets and iii) adding the possibility to use multivalued logic.
The technical features resulting from these improvements are illustrated on a
simple example network while their biological significance is assessed on a case
study, namely a published logic-based model of bladder tumorigenesis [16].
1.1 Handling asynchronous updating
To compute the behavior of a discrete dynamical system, such as a Boolean
network, its variables have to be iteratively updated. These iterative updates
can be made synchronously or not [17]. If all the variables are simultaneously
updated at each iteration then the network is synchronous, otherwise it is asyn-
chronous. Compared to an asynchronous updating, the synchronous one is easier
to compute. However, when the dynamics of a biological network is computed
synchronously, it is assumed that all its components evolve simultaneously, an
assumption which can be inappropriate according to what is modeled.
The asynchronous updating is frequently built so that one randomly selected
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variable is updated at each iteration. This allows to capture two important
features: i) biological entities do not necessarily evolve simultaneously and ii)
noise due to randomness can affect when biological interactions take place [18–
20]. This is particularly true at the molecular scale, such as with signaling
pathways, where macromolecular crowding and Brownian motion can impact
the firing of biochemical reactions [21].
Therefore, the choice between a synchronous and an asynchronous updating
may depend on the model, the computational resources and the acceptability
of synchrony. Knowing that the luxury is to have the choice, kali can now use
synchronous and asynchronous updating.
1.2 Managing basin sizes for therapeutic purpose
Until now, kali requires therapeutic bullets to remove all the attractors asso-
ciated with pathological phenotypes, here named pathological attractors. This
criterion for selecting therapeutic bullets is somewhat drastic. A smoother cri-
terion should enable to consider more targeting strategies and then more possi-
bilities for counteracting diseases. However, it could also unravel less effective
therapeutic bullets, but being too demanding potentially leads to no results and
the loss of nonetheless interesting findings.
The therapeutic potential of bullets could be assessed by estimating their
ability at reducing the size of the pathological basins, namely the basins of
pathological attractors. This criterion is more permissive since therapeutic bul-
lets no longer have to necessarily remove the pathological attractors. Reducing
the size of a pathological basin renders the corresponding pathological attractor
less reachable and then the associated pathological phenotype less likely. This
new criterion includes the previous one: removing an attractor means reducing
its basin to the empty set. Consequently, therapeutic bullets obtainable with
the previous criterion are still obtainable.
1.3 Extending to multivalued logic
One of the main limitations of Boolean models is that their variables can take
only two values, which can be too simplistic in some cases. Depending on what
is modeled, such as activity level of enzymes or abundance of gene products,
considering more than two levels can be better. Without leaving the logic-based
modeling formalism, one solution is to extend Boolean logic to multivalued
logic [22].
With multivalued logic, a finite number h of values in the interval of real
numbers [0; 1] is used, thus allowing variables to model more than two levels. For
example, the level 0.5 can be introduced to model partial activation of enzymes
or moderate concentration of gene products.
2 Methods
2.1 Additional definitions
In addition to the background introduced in the previous article [1] and briefly
recalled in Appendix 1 page 22, here are some supplementary definitions:
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• physiological state space: the state space Sphysio of the physiological
variant
• pathological state space: the state space Spatho of the pathological
variant
• testing state space: the state space Stest of the pathological variant
under the effect of a bullet
• physiological basin: the basin Bphysio,i of a physiological attractor
aphysio,i
• pathological basin: the basin Bpatho,i of a pathological attractor apatho,i
• n-bullet: a bullet made of n targets
2.2 Handling asynchronous updating
To incorporate asynchronous updating, the corresponding algorithms coming
from BoolNet were implemented into kali. BoolNet is an R [23] package for gen-
eration, reconstruction and analysis of Boolean networks [24]. Asynchronous
updating is implemented so that one randomly selected variable is updated at
each iteration. This random selection is made according to a uniform distribu-
tion and implies that the network is no longer deterministic. To do so, given a
Boolean network, BoolNet uses the three following functions:
• AsynchronousAttractorSearch: this function computes the attractor
set of a supplied Boolean network by using the two following functions
• ForwardSet: this function computes the forward reachable set (see be-
low) of a state and considers it as a candidate attractor
• ValidateAttractor: this function checks if a forward reachable set is a
terminal strongly connected component (terminal SCC, see below), that
is an attractor
The forward reachable set Fwdx ⊂ S of a state x ∈ S is the set made of the
states reachable from x, including x itself. A terminal SCC is a set tSCC ⊂ S
made of the forward reachable sets of its states: ∀x ∈ tSCC, Fwdx ⊂ tSCC.
As a consequence, when a terminal SCC is reached, the system can not escape
it: this is an attractor in the sense of asynchronous Boolean networks [25].
Asynchronous Boolean networks with random updating are not determin-
istic: their attractors are no longer deterministic sequences of states, namely
cycles, but terminal SCCs. To find such an attractor, a long random walk is
performed in order to reach an attractor with high probability. This candidate
attractor is then validated, or not, by checking if it is a terminal SCC.
2.3 Managing basin sizes for therapeutic purpose
To implement the new criterion for selecting therapeutic bullets, kali consid-
ers a bullet as therapeutic if it increases the union of the physiological basins⋃
Bphysio,i in the testing state space Stest without creating de novo attrac-
tors. Knowing that for kali an attractor is either physiological or pathological,
increasing
⋃
Bphysio,i is equivalent to decreasing
⋃
Bpatho,i.
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The goal is to increase the physiological part of the pathological state space,
or equivalently to decrease its pathological part. Consequently, a pathologically
disturbed biological network receiving such a therapeutic bullet tends to, but
not necessarily reaches, an overall physiological behavior.
However, as with the previous criterion, it does not ensure that all the phys-
iological attractors are preserved. A fortiori, it does not ensure that their basin
remains unchanged. It means that a therapeutic bullet can also alter the reach-
ability of the physiological attractors. Nevertheless, as with the previous cri-
terion, this is a matter of choice between a therapeutic bullet or no bullet at
all.
The therapeutic potential of a bullet is expressed by its gain. It is displayed
as follows:
x%→ y% with x = 100 ·
|
⋃
Bphysio,i|
|Spatho|
and y = 100 ·
|
⋃
Bphysio,i|
|Stest|
expressed in percents. Therefore, in order to increase the physiological part of
the pathological state space, a therapeutic bullet has to make y ≥ x.
Note that y = x is allowed. In this particular case, it is conceivable that the
size of several pathological basins changed while the size of their union did not.
In other words, the composition of the pathological part changed while its size
did not. It can be therapeutic if, for example, the basin of a weakly pathological
attractor increases at the expense of the basin of a heavily pathological attractor.
The increase of the physiological part of the pathological state space can
be subjected to a threshold δ: y ≥ x becomes y − x ≥ δ. As x and y, δ is
expressed in percents of the state space. This threshold is introduced to allow
the stringency of kali to be tuned. By the way, using this threshold also decreases
the probability to obtain misassessed therapeutic bullets due to roundoff errors,
or sampling errors when the state space is too big to compute trajectories from
each of the possible states.
A therapeutic bullet as defined by the previous criterion, namely which re-
moves all the pathological attractors, makes de facto
⋃
Bphysio,i = 100% of
Stest. As already mentioned, the previous criterion is included in this new one:
therapeutic bullets obtainable with the former are also obtainable with the lat-
ter.
It must be pointed out that the current implementation of the method de-
scribed in this article, namely kali, computes basin sizes by counting the number
of initial states leading to a given attractor. If these initial states are a subset of
the state space then basin sizes are estimations. Moreover, if an asynchronous
updating is used then the system is not deterministic, implying that an initial
state can lead to more than one attractor. Consequently, in those cases, basin
sizes and therapeutic gains are estimations also subjected to random variations.
In other words, concerning the calculation of basin sizes, the current imple-
mentation of kali is more an attractor reachability estimation than a true basin
size calculation. Nevertheless, speaking in terms of basins is kept in order to bet-
ter comply with the underlaying method, independently of its implementation
which is subjected to further improvements.
2.4 Extending to multivalued logic
Extending to multivalued logic requires suitable operators to be introduced.
One solution is to use an implementation of the Boolean operators which also
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works with multivalued logic, just as the Zadeh operators. These operators are
a generalization of the Boolean ones proposed for fuzzy logic by its pioneer Lotfi
Zadeh [26]. Their formulation is:
x ∧ y = min(x, y)
x ∨ y = max(x, y)
¬x = 1− x
With a h-valued logic, the size of the n-dimensional state space is hn, bring-
ing more computational difficulties than with Boolean logic. The same applies
to the testable bullets since there are hr possible modality arrangements and
then (n! ·hr)/(r! · (n− r)!) possible bullets, where r is the number of targets per
bullet (see below).
As introduced in the previous article [1] and recalled in Appendix 1 page
22, a bullet is a couple (ctarg, cmoda) where ctarg = (targ1, . . . , targr) is a com-
bination without repetition of r nodes and cmoda = (moda1, . . . ,modar) is an
arrangement with repetition of r perturbations, here termed modalities. modai
is intended to be applied on targi.
To illustrate how kali works with multivalued logic without overloading it, a
3-valued logic is used with {0, 0.5, 1} as domain of value: xi ∈ {0, 0.5, 1}. 0 and
1 have the same meaning as with Boolean logic. 0.5 is an intermediate truth
degree which can be interpreted as an intermediate level of activity/abundance
depending on what the variables refer to. By the way, S = {0, 0.5, 1}n and
modai ∈ {0, 0.5, 1}.
2.5 Example network
To conveniently illustrate the technical features resulting from the improvements
made on kali, a simple and fictive example network is used. A biological case
study is then proposed to address a concrete case, namely a published logic-
based model of bladder tumorigenesis [16]. The example network is depicted in
Figure 1 page 8.
Among the three improvements made on kali, only the asynchronous updat-
ing and the management of basin sizes are illustrated. Multivalued logic is a
straightforward extension of the Boolean case and is illustrated in Appendix 2
page 24. Below are the Boolean equations encoding the example network, also
available in text format in the supporting file example_equations.txt:
do = do
factory = factory
energy = factory ∨ (energy ∧ ¬task)
locker = ¬energy
releaser = do
sequester = ¬releaser
activator = do ∧ ¬locker
effector = activator ∧ ¬sequester
task = effector
7
Figure 1: This network, running in a fictive cell, controls the execution of a task
according to two inputs: i) the do instruction, which tells the task to be performed,
and ii) energy supply. The task consumes energy and must be prevented if no energy
is available, even if the do instruction is sent. The task is initiated by an effector,
which is maintained inactive by a sequester. The do instruction activates a releaser
which suppresses the sequestering activity of the sequester, thus releasing the effector.
However, to initiate the task and in addition to be released, the effector has also to be
activated by an activator. When released and activated, the effector initiates the task.
To ensure that the task is performed only if energy is available, a locker maintains the
activator in an inactive state if there is no energy, even if the do instruction is sent.
Concerning the factory, it supplies energy.
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The do instruction and the factory are the two inputs: they are constant
and therefore equal to themselves. The equation of energy tells that energy
is present if the factory is active, even when the task is running: the factory
has a sufficient production capacity. However, if the factory is not active then
energy disappears as soon as the task is initiated. Concerning the activator and
the effector, their equations tell that their respective inhibitor takes precedence:
whatever is the state of the other nodes, if the inhibitor is active then the target
is not.
The physiological variant fphysio is the network as is. The pathological
variant fpatho is the network plus a constitutive inactivation of the locker: the
execution of the task no longer considers if energy is available. Consequently,
flocker becomes locker = 0 in fpatho.
2.6 Case study: bladder tumorigenesis
The case study consists in running kali on a logic-based model of bladder tu-
morigenesis published by Elisabeth Remy and colleagues [16]. Elisabeth Remy
and colleagues have built an influence network linking three extracellular input
signals and one intracellular input event to three cellular output phenotypes.
The three extracellular input signals are growth stimulations, represented
by the EGFRstimulus and FGFR3stimulus parameters, and growth inhibi-
tions, mainly modeling TGF-β effects and represented by the GrowthInhibitors
parameter. The intracellular input event is DNA damage, represented by the
DNAdamage parameter. The three cellular output phenotypes are prolifera-
tion, growth arrest and apoptosis. The model integrates downstream effectors
of growth factor receptors such as Ras and PI3K, growth inhibitors such as
p14ARF and p16INK4a, and regulators of the cell cycle such as cyclinD1, E2F3
and pRb.
Some variables are ternary: they can take three possible values in order
to account for different effects depending on the activation level. These three
possible values are 0 and 1 as in the Boolean case, plus the additional level 2. As
in the model implementation performed by Elisabeth Remy and colleagues, these
ternary variables are translated into pairs of Boolean variables: one Boolean
variable per activation level, namely level 1 and level 2.
For example and according to the model, in its normal expression level (level
1, E2F1 = 1) the transcription factor E2F1 stimulates the expression of genes
supporting the cell cycle. However, when over-expressed (level 2, E2F1 = 2)
E2F1 stimulates the expression of genes supporting apoptosis. Consequently,
this ternary variable is translated into the pair of Boolean variables E2F1lvl1
and E2F1lvl2:
E2F1 = 1⇔ E2F1lvl1 = 1
E2F1 = 2⇔ E2F1lvl2 = 1
The variable modeling the output phenotypeApoptosis is one of these ternary
variables. The goal of Elisabeth Remy and colleagues was to relate apoptosis
to its trigger: p53-dependent apoptosis (Apoptosislvl1) and E2F1-dependent
apoptosis (Apoptosislvl2). However, in the present case study, only the cell fate
matters. These two trigger-dependent apoptosis are therefore merged into one
equation:
Apoptosis = Apoptosislvl1 ∨Apoptosislvl2
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Since the four inputs of the model are parameters, their respective value are
directly injected into the concerned equations so that no equations are dedicated
to them, thus reducing computational requirements. Again to reduce computa-
tional requirements and knowing that the three output phenotypes are readouts
not influencing other variables, their corresponding equation are put out of the
model and evaluated from the returned attractors once the run terminated:
Proliferation = CyclinE1 ∨ CyclinA
GrowthArrest = p21CIP ∨RB1 ∨ RBL2
Apoptosis = TP53 ∨ E2F1lvl2
Altogether, the above described adaptations made on the model of bladder
tumorigenesis by Elisabeth Remy and colleagues give a case study of 27 Boolean
equations. These equations are listed in Appendix 4 page 36, also available in
text format in the supporting file bladder_equations.txt. A network-based
representation is shown in Figure 2 page 10.
Figure 2: A network-based representation of the case study used to assess kali
on a concrete case. As explained in the text, it is derived from a published logic-
based model of bladder tumorigenesis [16]. Nodes represent Boolean variables while
edges indicate positive (black) and negative (red) influences. The input signals/events
growth stimulations, growth inhibitions and DNA damage are in red while the output
phenotypes proliferation, growth arrest and apoptosis are in green.
The physiological variant fphysio is the model as is. The pathological variant
fpatho is the model plus a deletion of the tumor suppressor gene CDKN2A, as
observed in bladder cancers [27, 28]. Note that the CDKN2A gene encodes
two growth inhibitors: p14ARF and p16INK4a. Consequently, the equations
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modeling these two variables become p14ARF = 0 and p16INK4a = 0 in
fpatho.
2.7 Implementation, code availability, license
kali is implemented in Go [29], tested with Go version go1.9.2 linux/amd64 under
Arch Linux [30]. kali is licensed under the GNU General Public License [31] and
freely available on GitHub at https://github.com/arnaudporet/kali. The
core of kali in pseudocode can be found in Appendix 3 page 28.
3 Results
3.1 Example network
3.1.1 Attractor sets
The example network is computed asynchronously over the whole state space,
namely 512 possible initial states, using Boolean logic. As explained in the
Methods section page 5, the asynchronous attractor search uses long random
walks to reach candidate attractors with high probability, and then checks if
they are indeed true attractors. Owing to the small size of the example network,
the length maxk of these random walks is set to 1 000 steps. With larger state
spaces, random walks should be longer to reach candidate attractors with high
probability.
The resulting attractors can be studied along four variables: the do instruc-
tion, the factory, the locker and the task. It is possible for energy to be present
without a running factory in the initial conditions. In this case, if the do instruc-
tion is sent then energy is consumed by the task but not remade by the factory.
With the physiological variant, the locker is expected to stop the task. However,
with the pathological variant where the locker is disabled, an abnormal behavior
is expected. Below are the computed attractors:
• Aphysio:
attractor basin (% of Sphysio) do factory energy locker task
aphysio1 17.8% 0 0 0 1 0
aphysio2 7.2% 0 0 1 0 0
aphysio3 25% 0 1 1 0 0
aphysio4 25% 1 0 0 1 0
aphysio5 25% 1 1 1 0 1
• Apatho:
attractor basin (% of Spatho) do factory energy locker task
apatho1 18.4% 0 0 0 0 0
aphysio2 6.6% 0 0 1 0 0
aphysio3 25% 0 1 1 0 0
apatho2 25% 1 0 0 0 1
aphysio5 25% 1 1 1 0 1
With the physiological variant, the behavior is as expected: the task runs
only if the do instruction is sent and only if the factory can remade the consumed
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energy. With the pathological variant, two pathological phenotypes represented
by apatho1 and apatho2 appear. apatho1 is pathological because the locker is
inactive while there is no available energy. However, it is weakly pathological
since the do instruction is not sent: there is no task to stop, an operational
locker is not mandatory.
In contrast, apatho2 is heavily pathological because an operational locker is
required to stop the task in absence of energy supply. In the fictive cell bearing
this example network, apatho2 could drain all its energy content, thus bringing
it to thermodynamical death. Moreover, apatho2 should not be neglected since
its basin occupies 25% of the pathological state space.
3.1.2 Therapeutic bullets
Bullets are assessed for their therapeutic potential on the pathological variant
fpatho according to the new criterion: decreasing the size of the pathological
basins Bpatho,i. All the bullets made of one to two targets are tested with a
threshold of 5%.
Choosing a threshold can appear somewhat arbitrary. It tells that if the
physiological part
⋃
Bphysio,i in the pathological state space Spatho occupies
x% of it, then to be therapeutic a bullet has to bring this value above (x+5)%
in the testing state space Stest. Therefore, the increases below this threshold
are considered not significant by kali. Even the choice of using a threshold can
be arbitrary, as discussed in the Methods section page 6.
Knowing that
⋃
Bphysio,i = 56.6% of Spatho, with a threshold of 5% the 1, 2-
bullets have to make
⋃
Bphysio,i ≥ (56.6+5)% = 61.6% of Stest to be considered
therapeutic. Below are the returned therapeutic bullets:
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• 1-therapeutic bullets:
bullet gain Bphysio1 Bphysio2 Bphysio3 Bphysio4 Bphysio5 Bpatho1 Bpatho2
do[0] 56.6% → 64.4% 0% 14.4% 50% 0% 0% 35.5% 0%
factory[1] 56.6% → 100% 0% 0% 50% 0% 50% 0% 0%
• 2-therapeutic bullets:
bullet gain Bphysio1 Bphysio2 Bphysio3 Bphysio4 Bphysio5 Bpatho1 Bpatho2
do[0] factory[1] 56.6% → 100% 0% 0% 100% 0% 0% 0% 0%
do[1] factory[1] 56.6% → 100% 0% 0% 0% 0% 100% 0% 0%
do[0] energy[1] 56.6% → 100% 0% 50% 50% 0% 0% 0% 0%
do[0] locker[0] 56.6% → 64.1% 0% 14.1% 50% 0% 0% 35.9% 0%
do[0] releaser[0] 56.6% → 62.9% 0% 12.9% 50% 0% 0% 37.1% 0%
do[0] sequester[1] 56.6% → 62.5% 0% 12.5% 50% 0% 0% 37.5% 0%
do[0] activator[0] 56.6% → 64.8% 0% 14.8% 50% 0% 0% 35.2% 0%
do[0] effector[0] 56.6% → 67.8% 0% 17.8% 50% 0% 0% 32.2% 0%
do[0] task[0] 56.6% → 73.2% 0% 23.2% 50% 0% 0% 26.8% 0%
factory[1] energy[1] 56.6% → 100% 0% 0% 50% 0% 50% 0% 0%
factory[1] locker[0] 56.6% → 100% 0% 0% 50% 0% 50% 0% 0%
where x[y] means that the variable x has to be set to the value y. For example, the therapeutic bullet do[0] factory[1] suggests to abolish
the do instruction while maintaining the factory active.
1
3
All the returned therapeutic bullets not removing all the pathological at-
tractors exhibit the ability to suppress the basin of apatho2 while increasing the
one of apatho1. Certainly, removing all the pathological attractors should be
better, but knowing the apatho2 is more pathological than apatho1, such ther-
apeutic bullets can nevertheless be interesting. With the previous criterion,
namely removing all the pathological attractors, these therapeutic bullets are
not obtainable, thus highlighting fewer therapeutic strategies.
Some of the found therapeutic bullets enable physiological attractors re-
quired by the pathological variant to react properly to the do instruction. For
example, the therapeutic bullet factory[1] enables aphysio3 and aphysio5, cor-
responding respectively to “no do, no task” and “do the task, energy supply”.
However, the remaining of the therapeutic bullets, such as do[0] releaser[0] or
do[1] factory[1], either disable or force the do instruction, thus either suppress-
ing or forcing the task. A network unable at performing the task or, at the
opposite, permanently doing it may not be therapeutically interesting, even if
energy is supplied.
None of the found therapeutic bullets suggest to reverse the constitutive in-
activation of the locker. This highlights that applying the opposite action of
a pathological disturbance is not necessarily a therapeutic solution, which can
appear counterintuitive. This is because biological entities subjected to patho-
logical disturbances belong to complex networks exhibiting behaviors which
can not be predicted by mind [32, 33]. In such context, computational tools
and their growing computing capabilities can help owing to their integrative
power [34–38].
Also, none of the found therapeutic bullets allow the recovery of all the
physiological attractors: there are no golden bullets. In a general manner, the
components of biological networks should be able to take several states, such as
enzymes which should be active when suitable. Consequently, healing a patho-
logically disturbed biological network by maintaining some of its components
in a particular state should not allow the recovery of a complete and healthy
behavior. This is a limitation of the method implemented in kali.
This limitation is common in biomedicine while not necessarily being an
issue. For example, statins are well known lipid-lowering drugs widely used in
cardiovascular diseases with proven benefits [39, 40]. They inhibit an enzyme,
the HMG-CoA reductase, and they do it constantly, just as the targets are
modulated in the therapeutic bullets returned by kali. The HMG-CoA reductase
is component of a complex metabolic network and maintaining it in an inhibited
state should not allow this network to run properly, maybe causing some adverse
effects. Nevertheless, such as with all drugs, this is a matter of benefit-risk ratio.
All of this is to point that there are no perfect strategies for counteracting
diseases and that computational tools, such as kali, can help scientists but can
certainly not replace their expertise. Human expertise is mandatory to assess
the returned predictions according to a concrete setting, and ultimately to take
decisions.
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3.2 Case study: bladder tumorigenesis
3.2.1 Attractor sets
The case study is computed asynchronously using Boolean logic. The state
space being quite big with 134 217 728 possible states, to compute an attractor
set kali performs random walks starting from 1 000 randomly selected initial
states. A bigger state space also requires these random walks to be longer in
order to reach candidate attractors with high probability. The length maxk of
the random walks is then increased to 10 000 steps.
The 4 input parameters of the model are tuned to simulate a biological
situation where undamaged cells receive both growth stimulating and growth
inhibiting signals from their environment:
EGFRstimulus = 1
FGFR3stimulus = 1
GrowthInhibitors = 1
DNAdamage = 0
This input configuration aims at predicting the possible responses of the
model to opposite growth instructions. In a cancerous setting, it is desirable
that the growth inhibiting signal takes precedence over the stimulating one.
With the pathological variant where the two growth inhibitors p14ARF and
p16INK4a are absent, this desired precedence might be compromised in favor
of tumorigenesis, thus correlating with the observed CDKN2A gene deletion in
bladder cancers [27, 28].
The phenotypes associated with the returned attractors are evaluated using
their respective equation once the run terminated, as explained in the Methods
section page 10. Below are the computed attractors together with their pheno-
types and basins, expressed in percents of the corresponding state space:
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Aphysio Apatho
name aphysio1 aphysio2 aphysio3 aphysio1 apatho1
basin 10.7% 74.5% 14.8% 65.4% 34.6%
phenotype GA GA P GA P
AKT 0 0 0 0 0
ATMlvl1 0 0 0 0 0
ATMlvl2 0 0 0 0 0
CDC25A 0 0 1 0 1
CHEK1/2lvl1 0 0 0 0 0
CHEK1/2lvl2 0 0 0 0 0
CyclinA 0 0 1 0 1
CyclinD1 0 0 0 0 1
CyclinE1 0 0 1 0 1
E2F1lvl1 0 0 1 0 1
E2F1lvl2 0 0 0 0 0
E2F3lvl1 0 1 1 0 1
E2F3lvl2 0 0 0 0 0
EGFR 0 0 0 0 0
FGFR3 1 1 1 1 1
GRB2 0 0 0 0 0
MDM2 0 0 0 0 0
p14ARF 0 0 1 0 0
p16INK4a 0 1 1 0 0
p21CIP 1 1 0 1 0
PI3K 0 0 0 0 0
PTEN 0 0 0 0 0
RAS 1 1 1 1 1
RB1 1 0 0 1 0
RBL2 1 1 0 1 0
SPRY 1 1 1 1 1
TP53 0 0 0 0 0
where GA means growth arrest and P means proliferation.
The physiological variant is able to exhibit the two possible responses ac-
cording to the input configuration: proliferation, represented by aphysio3, and
growth arrest, represented by aphysio1 and aphysio2. Growth arrest occupies
85.2% of the physiological state space, suggesting that normal cells are more
likely to comply with growth inhibiting signals than with stimulating ones.
With the pathological variant modeling cells whose the two growth inhibitors
p14ARF and p16INK4a are lost, the two possible responses are still present
with again growth arrest being more likely than proliferation. Even if aphysio2
disappears, growth arrest is still possible with aphysio1 whose the basin increases
from 10.7% in Sphysio to 65.4% in Spatho. The proliferating phenotype is also
still possible but through the pathological attractor apatho1 which, in a way,
replaces the physiological attractor aphysio3.
However, the global tendency toward growth arrest significantly decreases:
proliferation is more than twice likely in the pathological variant than in the
physiological one with a shift from 14.8% in Sphysio to 34.6% in Spatho. There-
fore, such pathological cells might be less responsive to growth inhibiting signals
and more apt at proliferating, which is a major concern in tumorigenesis and
consistent with the loss of two growth inhibitors.
To ensure that browsing the state space by performing 1 000 random walks
of 10 000 steps is sufficient to find all the attractors while estimating their
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basin with little variability, the physiological and pathological attractor sets
were computed 100 times each:
set attractor basin (% of S)
Aphysio
aphysio1 10.518 ± 0.833
aphysio2 73.462 ± 1.24
aphysio3 16.02 ± 1.091
Apatho
aphysio1 65.037 ± 1.687
apatho1 34.963 ± 1.687
These results indicate that, in the present case study, browsing the state
space by performing 1 000 random walks of 10 000 steps is enough robust to
obtain reproducible results. Indeed, at each time, the same attractors are found:
no attractor is missed. Moreover, the means of the basin estimations exhibit
low standard deviations: basin estimations are subjected to variability but are
nonetheless reliable.
3.2.2 Therapeutic bullets
As in the example network, bullets are assessed for their therapeutic potential
on the pathological variant fpatho according to the new criterion: increasing the
physiological part
⋃
Bphysio,i in the testing state space Stest with a threshold
of 5%. It means that therapeutic bullets have to push
⋃
Bphysio,i from 65.4%
in Spatho to at least 65.4 + 5 = 70.4% in Stest.
This case study belonging to a cancerous setting, it is desirable that thera-
peutic bullets also promote growth arrest in order to slow down tumorigenesis.
In terms of basins and attractors, it means that interesting therapeutic bul-
lets should decrease Bpatho1, avoid aphysio3, increase Bphysio1 and reintroduce
aphysio2. Such therapeutic bullets could be qualified as anti-proliferative.
All the 1 458 bullets made of one to two targets are tested. Among them, kali
finds 9 1-therapeutic bullets and 174 2-therapeutic bullets listed in the support-
ing files bladder_B_therap_1.txt and bladder_B_therap_2.txt respectively.
In addition to increasing the physiological part, all the returned therapeutic
bullets are anti-proliferative. Indeed, all of them do not reintroduce aphysio3
and decrease Bpatho1, thus promoting growth arrest through aphysio1 and/or
aphysio2.
For example, the two following 1-therapeutic bullets increase Bphysio1 while
decreasing Bpatho1, thus exhibiting anti-proliferative effect as expected when
targeting the well known growth promoting PI3K/Akt pathway [41]:
bullet gain Bphysio1 Bphysio2 Bphysio3 Bpatho1
AKT [0] 65.4% → 89.3% 89.3% 0% 0% 10.7%
PI3K[0] 65.4% → 86% 86% 0% 0% 14%
Below is an other interesting 1-therapeutic bullet predicting that inhibiting
CDC25A is anti-proliferative:
bullet gain Bphysio1 Bphysio2 Bphysio3 Bpatho1
CDC25A[0] 65.4% → 100% 100% 0% 0% 0%
This therapeutic bullet is able to definitively suppress proliferation by mak-
ing Bphysio1 = 100% of Stest. It makes sense since the tyrosine phosphatase
CDC25A can activate several cyclin-dependent kinases (CDKs) which, with
their cyclin partners, promote cell cycle and then growth [42]. This prediction
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correlates with biological knowledge about CDC25A inhibitors as potential an-
ticancer agents [43]. For example, it is demonstrated that inhibiting CDC25A
can suppress the growth of hepatocellular carcinoma cells [44, 45]. Moreover,
a recent work was specially dedicated to the synthesis of anticancer agents in-
hibiting the CDC25A/B phosphatases [46].
This highlights that dry-lab predictions consistent with factual evidences
coming from wet-lab experiments are obtainable through kali, provided that
the underlaying model is consistent too. Note that this does not imply that
all the predictions are correct: needless to say that biological interpretation by
experts is still mandatory.
The 2-therapeutic bullets also bring some interesting predictions. For exam-
ple, they indicate that sprouty (SPRY) could be a therapeutic target but only
in combination with another one: there are no 1-therapeutic bullets containing
it. Sprouty negatively regulates mitogen-activated protein kinase (MAPK) sig-
naling pathways downstream of growth factor receptors and is down-regulated in
many cancers [47]. Consequently, stimulating sprouty should be anti-proliferative
and this is what suggest the two following therapeutic bullets, even if the gain
is relatively minor:
bullet gain Bphysio1 Bphysio2 Bphysio3
Bpatho1
E2F3lvl2[0] SPRY [1] 65.4% → 70.5% 70.5% 0% 0%
29.5%
MDM2[0] SPRY [1] 65.4% → 71.7% 71.7% 0% 0%
28.3%
These two therapeutic bullets indicate that stimulating sprouty should be
done along with an inhibition of MDM2 or E2F3. As with CDC25A, this pre-
diction correlates with biological knowledge: MDM2 is a major inhibitor of the
well known tumor suppressor p53 [48] while E2F3 is a required transcription
factor for the cell cycle [49]. However, only the level 2 of E2F3 is concerned,
meaning that only its over-expression should be prevented. In other words, this
is not an inhibition of E2F3 but rather the prevention of its over-expression, if
any.
In the returned therapeutic bullets there are also intriguing results such as
the following one:
bullet gain Bphysio1 Bphysio2 Bphysio3 Bpatho1
FGFR3[1] 65.4% → 74.1% 74.1% 0% 0% 25.9%
This therapeutic bullet moderately increases Bphysio1 at the expense of Bpatho1,
thus promoting growth arrest. However, FGFR3 is a growth factor receptor
and is frequently subjected to activating mutations in low grade bladder cancers
[50]. Therefore, stimulating FGFR3 should promote proliferation, not growth
arrest. However, Elisabeth Remy and colleagues have implemented a negative
crosstalk from FGFR3 to the growth factor receptor EGFR in their model.
This negative crosstalk may explain why stimulating FGFR3 is predicted to be
anti-proliferative.
Indeed, EGFR[0] is one of the returned therapeutic bullet and represent
a direct inhibition of EGFR, a well studied target in cancer therapies [51, 52].
Consequently and according to the model, FGFR3[1] can be interpreted as an
indirect inhibition of EGFR, especially since these two therapeutic bullets have
almost identical effects in magnitude:
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bullet gain Bphysio1 Bphysio2 Bphysio3 Bpatho1
EGFR[0] 65.4% → 75.4% 75.4% 0% 0% 24.6%
Finally, it should be noted that the three following bullets are not predicted
therapeutic by kali: p14ARF [1], p16INK4a[1] and p14ARF [1] p16INK4a[1].
As with the example network, this suggests that applying the opposite action of
the pathological disturbance is not necessarily a therapeutic solution. Moreover,
and again as with the example network, none of the found therapeutic bullets
allow the recovery of all the physiological attractors: golden bullets seem to be
as idealistic as golden pills.
3.3 Computation times
The results presented in this article were obtained on a laptop with 16GB of
RAM and an Intel Core i7-6600U processor. There are two kali parameters
strongly influencing computation times. These two parameters control the at-
tractor search and are:
• maxS : the maximum number of initial states to use when computing an
attractor set
• maxk: the length of the random walks performed to reach candidate at-
tractors
The asynchronous attractor search consists in performing maxS random
walks of maxk steps. Knowing that such a search is performed for computing
an attractor set and that one attractor set is computed per tested bullet, the
computation time can greatly increase with maxS and/or maxk. By the way,
computation times also increase with ntarg, maxtarg and maxmoda, three kali
parameters controlling how much bullets are tested:
• ntarg: the number of targets per bullet
• maxtarg: the maximum number of target combinations to test
• maxmoda: the maximum number of modality arrangements to test
The used logic can also increase computation times because the size of the
state space is hn, where n is the number of nodes in the network and h the
number of possible values for the variables. For example, h = 2 with Boolean
logic and h = 3 with 3-valued logic. h can also increase the number of testable
bullets, and then computation times, since there are (n! · hntarg )/(ntarg! · (n −
ntarg)!) possible bullets.
Below are the computation times of the runs performed for this article:
example network example network case study
(Boolean) (3-valued) (Boolean)
maxS 512 (all) 1 000 1 000
maxk 1 000 1 000 10 000
1-bullets 18 (all) 27 (all) 54 (all)
2-bullets 144 (all) 324 (all) 1 404 (all)
Aphysio 130ms 187ms 6s89ms
Apatho 109ms 218ms 6s55ms
Btherap (ntarg = 1) 2s510ms 6s775ms 5m57s950ms
Btherap (ntarg = 2) 19s133ms 1m23s526ms 2h43m36s709ms
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4 Conclusion
kali can now work on both synchronous and asynchronous Boolean networks.
This is probably the most required improvement since asynchronous updating
is frequently used in the scientific community and might be better realistic than
synchrony, as discussed in the Introduction section page 3. Consequently, a
computational tool aimed at working on models built by the scientific commu-
nity, such as kali, has to handle this updating scheme.
Also note that there are more than one asynchronous updating scheme. The
one implemented in kali is the most popular and is named the general asyn-
chronous updating: one randomly selected variable is updated at each iteration.
However, other asynchronous updating methods exist. For example, with the
random order updating, all the variables are updated at each iteration along a
randomly selected order. Implementing various asynchronous updating schemes
in kali could be a required future improvement.
kali now uses a new criterion for assessing therapeutic bullets. This new
criterion brings a wider range of targeting strategies intended to push patho-
logical behaviors toward physiological ones. It is based on a more permissive
assumption stating that reducing the reachability of pathological attractors is
therapeutic.
For an in silico tool such as kali, being a little bit more permissive can
be important since the findings obtained by simulations have to outlive the
bottleneck separating predictions and reality. With a too strict assessment of
therapeutic bullets, the risk of highlighting too few candidate targets or to miss
some interesting ones can be high. Moreover, predicted does not necessarily
mean true: a prediction of apparently poor interest can reveal itself of great
interest, and vice versa.
This new criterion also brings a finer assessment of therapeutic bullets since
all the possible increases of
⋃
Bphysio,i in Stest are considered. With the previous
criterion, there was only one therapeutic potential:
⋃
Bphysio,i = 100% of Stest,
thus reducing the assessment of bullets to therapeutic or not. Things are not so
dichotomous but rather nuanced: the assessment of therapeutic bullets should
be nuanced too.
kali can now work with multivalued logic. Allowing variables to take an arbi-
trary finite number of values should enable to more accurately model biological
processes and produce more fine-tuned therapeutic bullets. However, this accu-
racy and fine-tuning are at the cost of an increased computational requirement.
Indeed, the size of the state space depends on the size of the model and the
used logic.
Consequently, the size of the model and the used logic should be balanced:
the smaller the model is, the more variables should be finely valued. For exam-
ple, for an accurate therapeutic investigation, the model should only contain the
essential and specific pieces of the studied pathological mechanisms modeled by
a finely valued logic. On the other hand, for a broad therapeutic investigation,
a more exhaustive model can be used but modeled by a coarse-grained logic.
Note that the ultimate multivalued logic is the infinitely valued one, which
is fuzzy logic [53]. With fuzzy logic, the whole interval of real numbers [0; 1] is
used to valuate variables, which might bring the best accuracy for the qualitative
modeling formalism [54–56]. However, using such a continuous logic implies to
leave the relatively convenient discrete paradigm to enter the continuous one
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where, for example, the state space is infinite.
kali also demonstrates that it is able at predicting therapeutic bullets con-
sistent with the underlaying model, with biological knowledge and with exper-
imental evidences. For example, in the bladder tumorigensis case study, kali
returned therapeutic bullets inhibiting the PI3K/Akt pathway or the CDC25A
tyrosine phosphatase, two documented targets in cancer therapies.
Even the surprising FGFR3[1] therapeutic bullets, which suggests to stimu-
late a growth factor receptor for promoting growth arrest, is consistent with the
underlaying model. Indeed, according to this model, it appears that FGFR3[1]
is founded in a negative crosstalk from FGFR3 to EGFR, thus indirectly in-
hibiting the growth factor receptor EGFR, which is also a documented target
in cancer therapies.
Two additional improvements are envisioned for kali. The first one is to allow
therapeutic bullets to create new attractors, namely de novo attractors. It is
conceivable that a bullet can greatly decrease pathological basins while creating
a new attractor not belonging to the physiological variant nor to the pathological
one. Such a de novo attractor is currently tagged by kali as not physiological
and then pathological, thus rejecting the concerned bullet. However, if a de
novo attractor is weakly pathological and induced by a bullet greatly decreasing
the basin of other and heavier pathological attractors, such a case should be
retained.
The second envisioned improvement is to allow partial matching when check-
ing if an attractor is associated with a physiological phenotype by comparing it
to the physiological attractors. Currently, an attractor which does not match a
physiological attractor is considered pathologic. However, it is conceivable that
some variables not exhibiting a physiological behavior in an attractor do not
pathologically impact its associated phenotype. To allow such a case to be con-
sidered, some variables within attractors should be allowed to not be matched
when assessing the associated phenotype.
This suggests the concept of decisive variables, namely variables whose the
behavior in the attractors is sufficient to biologically interpret the associated
phenotypes. Elisabeth Remy and colleagues have already implemented this
distinction in their model of bladder tumorigenesis used in the present article as
case study: decisive variables are those belonging to the equations of the three
output phenotypes. Therefore, kali could allow non-decisive variables to not be
matched.
Ultimately, this could allow the modeler to specify himself/herself what a
physiological attractor is without having to consider a physiological and a patho-
logical variant. This could also allow to no longer think in terms of physiological
versus pathological attractors but just desirable ones. Moreover, implementing
the second envisioned improvement could greatly facilitate the implementation
of the first one since the goal would become to obtain desired attractors regard-
less if they are de novo or not.
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5 Appendix 1: recall of previous concepts
Below are some important concepts introduced in the previous article where the
complete background was presented [1].
5.1 Biological networks
A network is a directed graph G = (V,E) where V = {v1, . . . , vn} is the set
containing the nodes of the network and E = {(vi,1, vj,1), . . . , (vi,m, vj,m)} is the
set containing the edges linking these nodes. In practice, nodes represent entities
while edges represent binary relations R ⊂ V 2 involving them: vi R vj [57]. It
indicates that the node vi exerts an influence on the node vj . For example, in
gene regulatory networks [58], vi can be a transcription factor while vj a gene
product. The edges are frequently signed so that they indicate if vi exerts a
positive or a negative influence on vj , such as an activation or an inhibition.
5.2 Boolean networks
A Boolean network is a network where nodes are Boolean variables xi and edges
(xi, xj) are the is input of relation: xi is input of xj . Each variable xi has
bi ∈ [[0, n]] inputs influencing its state. Note that bi = 0 is possible. In this
case, xi is an input of the network. Depending on the updating scheme, at
each iteration k ∈ [[k0, kend]] one or more xi are updated using their associated
Boolean transition function fi. This function uses Boolean operators, typically
∧ (and), ∨ (or) and ¬ (not), to specify how the inputs xi,1, . . . , xi,bi of xi have
to be related to compute its value, as in the following pseudocode representing
a synchronous updating:
for k ← k0, . . . , kend
x1 ← f1(x1,1, . . . , x1,b1)
...
xn ← fn(xn,1, . . . , xn,bn)
end for
which can be written in a more concise form:
for k ← k0, . . . , kend
x← f (x)
end for
where f = (f1, . . . , fn) is the Boolean transition function of the network and
x = (x1, . . . , xn) is its state vector. The value of the state vector belongs to the
state space S = {0, 1}n, which is the set containing all the possible states of the
network.
The set A = {a1, . . . , ap} containing the attractors of the network is its
attractor set. An attractor ai is a collection of states (x1, . . . ,xq) such that
once the system reaches a state xj ∈ ai, it can subsequently visit the states of
ai but no other ones: the system can not escape. The set Bi ⊂ S containing the
states x ∈ S from which ai can be reached is its basin of attraction, or simply
basin.
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5.3 Definitions
• physiological phenotype: a phenotype which does not impair the life
quantity/quality of the organism which exhibits it
• pathological phenotype: a phenotype which impairs the life quantity/
quality of the organism which exhibits it
• variant (of a biological network): given a biological network, a variant
is one of its versions, namely the network plus eventually some modifica-
tions
• physiological variant: a variant which produces only physiological phe-
notypes, this is the biological network as it should be, the one of healthy
organisms
• pathological variant: a variant which produces at least one pathological
phenotype, this is a dysfunctional version of the biological network, a
version found in ill organisms
• physiological attractor set: the attractor set Aphysio of the physiolog-
ical variant
• pathological attractor set: the attractor set Apatho of the pathological
variant
• physiological Boolean transition function: the Boolean transition
function fphysio of the physiological variant
• pathological Boolean transition function: the Boolean transition
function fpatho of the pathological variant
• physiological attractor: an attractor ai such that ai ∈ Aphysio, note
that it does not exclude the possibility that ai ∈ Apatho in addition to
ai ∈ Aphysio
• pathological attractor: an attractor ai such that ai /∈ Aphysio
• modality: the perturbation modai ∈ {0, 1} applied on a node vj of the
network, either activating (modai = 1) or inactivating (modai = 0), at
each iteration modai overwrites fj(x) making xj = modai
• target: a node targi of the network on which a modality modai is applied
• bullet: a couple (ctarg, cmoda) where ctarg = (targ1, . . . , targr) is a com-
bination without repetition of r targets and cmoda = (moda1, . . . ,modar)
is an arrangement with repetition of r modalities, modai is intended to be
applied on targi
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6 Appendix 2: multivalued case
Below is the multivalued version of the example network:
do = do
factory = factory
energy = max(min(energy,1− task), factory)
locker = 1− energy
releaser = do
sequester = 1− releaser
activator = min(do, 1− locker)
effector = min(activator, 1− sequester)
task = effector
where the Boolean operators are replaced by the Zadeh ones.
To take advantage of multivalued logic, flocker becomes locker = min(1 −
energy, 0.5) in fpatho. This equation tells that the locker is actionable when
required, namely when there is no energy, but that it is unable at being fully
operational due to some pathological defects: the maximal value of flocker in
fpatho is 0.5.
As mentioned in the article, 0.5 can be interpreted as an incomplete activa-
tion/inhibition depending on what is modeled. Consequently, in the pathological
variant, the activator is at most partly inhibited by the locker when no energy
is available, allowing the task to be nevertheless performed. However, in this
case, the task is itself moderately performed.
6.1 Attractor sets
The example network is computed asynchronously using a 3-valued logic. To
compute an attractor set, kali performs 1 000 random walks of 1 000 steps.
Below are the returned attractors:
• Aphysio:
attractor basin (% of Sphysio) do factory energy locker task
aphysio1 6.1% 0 0 0 1 0
aphysio2 4.5% 0 0 0.5 0.5 0
aphysio3 2.5% 0 0 1 0 0
aphysio4 9.7% 0 0.5 0.5 0.5 0
aphysio5 1.8% 0 0.5 1 0 0
aphysio6 10.8% 0 1 1 0 0
aphysio7 6.5% 0.5 0 0 1 0
aphysio8 4.8% 0.5 0 0.5 0.5 0.5
aphysio9 10.3% 0.5 0.5 0.5 0.5 0.5
aphysio10 10.6% 0.5 1 1 0 0.5
aphysio11 7.3% 1 0 0 1 0
aphysio12 3.2% 1 0 0.5 0.5 0.5
aphysio13 10.3% 1 0.5 0.5 0.5 0.5
aphysio14 11.6% 1 1 1 0 1
• Apatho:
24
attractor basin (% of Spatho) do factory energy locker task
apatho1 6.2% 0 0 0 0.5 0
aphysio2 4.7% 0 0 0.5 0.5 0
aphysio3 2.2% 0 0 1 0 0
aphysio4 9.7% 0 0.5 0.5 0.5 0
aphysio5 1.8% 0 0.5 1 0 0
aphysio6 10.8% 0 1 1 0 0
apatho2 5.5% 0.5 0 0 0.5 0.5
aphysio8 5.8% 0.5 0 0.5 0.5 0.5
aphysio9 10.3% 0.5 0.5 0.5 0.5 0.5
aphysio10 10.6% 0.5 1 1 0 0.5
apatho3 7.3% 1 0 0 0.5 0.5
aphysio12 3.2% 1 0 0.5 0.5 0.5
aphysio13 10.3% 1 0.5 0.5 0.5 0.5
aphysio14 11.6% 1 1 1 0 1
aphysio1, aphysio3, aphysio6, aphysio11 and aphysio14 are the physiological at-
tractors found in the Boolean case with a different numbering due to additional
attractors coming from multivalued logic. Indeed, given that {0, 1} ⊂ {0, 0.5, 1}
and that the Zadeh operators also work with Boolean logic, the Boolean results
are still obtainable. The same does not apply to the pathological attractors
because flocker in fpatho differs between the Boolean and multivalued cases.
For example, aphysio13 indicates that the do instruction is sent while energy
is partly supplied. Consequently, the locker is partly activated resulting in
a partial inhibition of the activator. The task is thus moderately performed
despite full do instruction, hence coping with moderate energy supply.
Concerning the pathological attractors, as an example apatho3 indicates that
the do instruction is sent in absence of energy supply. Consequently, the locker
should be fully activated to prevent the task. However, due to some pathological
defects, the locker is at most partly activated. The task is then performed in
absence of energy. However, since the locker is partly operational, the task is
not performed at its maximum rate, maybe limiting pathological consequences.
Among the pathological attractors, apatho1 can be considered weakly patho-
logical. Indeed, in apatho1 the locker should be fully activated since there is
no energy. However, there is no do instruction and therefore no task to stop.
On the other hand, apatho2 and apatho3 are more pathological since the task is
performed while no energy is available.
6.2 Therapeutic bullets
All the bullets made of one to two targets are tested with a threshold of 5%.
Below are the returned therapeutic bullets:
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• 1-therapeutic bullets:
bullet gain Bphysio1 Bphysio2 Bphysio3 Bphysio4 Bphysio5 Bphysio6 Bphysio7 Bphysio8 Bphysio9
Bphysio10 Bphysio11 Bphysio12 Bphysio13 Bphysio14 Bpatho1 Bpatho2 Bpatho3
factory[0.5] 81% → 100% 0% 0% 0% 29.3% 6.1% 0% 0% 0% 32.2%
0% 0% 0% 32.4% 0% 0% 0% 0%
factory[1] 81% → 100% 0% 0% 0% 0% 0% 35.4% 0% 0% 0%
32.2% 0% 0% 0% 32.4% 0% 0% 0%
• 2-therapeutic bullets:
bullet gain Bphysio1 Bphysio2 Bphysio3 Bphysio4 Bphysio5 Bphysio6 Bphysio7 Bphysio8 Bphysio9
Bphysio10 Bphysio11 Bphysio12 Bphysio13 Bphysio14 Bpatho1 Bpatho2 Bpatho3
do[0] factory[0.5] 81% → 100% 0% 0% 0% 84% 16% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0% 0%
do[0] factory[1] 81% → 100% 0% 0% 0% 0% 0% 100% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0% 0%
do[0.5] factory[0.5] 81% → 100% 0% 0% 0% 0% 0% 0% 0% 0% 100%
0% 0% 0% 0% 0% 0% 0% 0%
do[0.5] factory[1] 81% → 100% 0% 0% 0% 0% 0% 0% 0% 0% 0%
100% 0% 0% 0% 0% 0% 0% 0%
do[1] factory[0.5] 81% → 100% 0% 0% 0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 100% 0% 0% 0% 0%
do[1] factory[1] 81% → 100% 0% 0% 0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 100% 0% 0% 0%
do[0] energy[1] 81% → 100% 0% 0% 34.9% 0% 32.1% 33% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0% 0%
do[0] task[0] 81% → 89% 0% 11.6% 12.3% 21.3% 10.8% 33% 0% 0% 0%
0% 0% 0% 0% 0% 11% 0% 0%
do[0.5] task[0.5] 81% → 89.4% 0% 0% 0% 0% 0% 0% 0% 24.3% 32.1%
33% 0% 0% 0% 0% 0% 10.6% 0%
factory[0] energy[0.5] 81% → 100% 0% 35.4% 0% 0% 0% 0% 0% 32.2% 0%
0% 0% 32.4% 0% 0% 0% 0% 0%
factory[0.5] energy[0.5] 81% → 100% 0% 0% 0% 35.4% 0% 0% 0% 0% 32.2%
0% 0% 0% 32.4% 0% 0% 0% 0%
factory[1] energy[1] 81% → 100% 0% 0% 0% 0% 0% 35.4% 0% 0% 0%
32.2% 0% 0% 0% 32.4% 0% 0% 0%
factory[1] locker[0] 81% → 100% 0% 0% 0% 0% 0% 35.4% 0% 0% 0%
32.2% 0% 0% 0% 32.4% 0% 0% 0%
2
6
For example, the therapeutic bullet factory[1] locker[0] is interesting. It
suppresses all the pathological attractors while maintaining three physiological
attractors allowing the pathological variant to properly respond to the three
possible levels of the do instruction. Moreover, the basins of these three phys-
iological attractors, namely aphysio6, aphysio10 and aphysio14, equally span the
state space, making them equally reachable.
On the other hand, the therapeutic bullet do[0.5] factory[0.5] seems to be
less interesting. While this bullet also suppresses all the pathological attrac-
tors, it enables only one physiological attractor. In this physiological attractor,
namely aphysio9, all the variables are at their intermediate level: the network
can not fulfill its switching function.
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7 Appendix 3: core of kali
Below is the core of kali in pseudocode derived from its Go [29] sources, freely
available on GitHub at https://github.com/arnaudporet/kali under the
GNU General Public License [31]. Note that the code may have evolved since
the publication of the present article.
7.1 Defined types
structure Attractor// an attractor
field Name// its name, either aphysio or apatho
field Basin// the size of its basin, in percents of the state space
field States// its states, as a matrix of one state per row
end structure
structure Bullet// a bullet
field Targ// its target combination, as a vector
field Moda// its modality arrangement, as a vector
field Gain// its gain, see below
field Cover// the size of each basin under its influence, see below
end structure
b.Gain is a vector (gain1, gain2) where:
• gain1 is the size of
⋃
Bphysio,i in Spatho
• gain2 is the size of
⋃
Bphysio,i in Stest
in % of Spatho and % of Stest respectively.
b.Cover is a vector containing the size of the physiological and pathological
basins in the testing state space, in percents of it.
7.2 Parameters
nodes// the node names, as a vector
Ω// the domain of the used logic, as a vector
sync// use synchronous updating (sync = 1) or not (sync = 0)
whole// build the whole state space (whole = 1) or not (whole = 0)
maxS// the maximal size of the state space sample when whole = 0
maxk// the number of steps for the random walks (asynchronous only)
ntarg// the number of targets per bullet
maxtarg// the maximum number of target combinations to test
maxmoda// the maximum number of modality arrangements to test
δ// the threshold for a bullet to be therapeutic, in percents of the state space
When whole = 0, a subset of the state space is built. This subset contains the
initial states from which trajectories are performed. These trajectories are used
for computing an attractor set, that is to reach the attractors. Note that these
trajectories are free to evolve in all the state space. In other words, kali does
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not run on a subset of the state space, these are the initial states which are a
subset of the state space.
To be considered therapeutic, a bullet has to make gain2− gain1 ≥ δ while not
creating de novo attractors.
7.3 Functions
function DoTheJob(fphysio, fpatho, ntarg,maxtarg,maxmoda,maxS ,maxk, δ,
sync, nodes,Ω, whole)
// do the job, this is the main function
n← Size(nodes)// the dimension of the state space S
select whole
case 0// build a sample of S
S ← GenArrangs(Ω, n,maxS)
case 1// build all S
S ← GenSpace(Ω, n)
end select
Aphysio ← ComputeAttractorSet(fphysio, S,∅,maxk, 0, sync, ∅)
Apatho ← ComputeAttractorSet(fpatho, S,∅,maxk, 1, sync,Aphysio)
Aversus ← GetV ersus(Apatho)// the pathological attractors, see below
Ctarg ← GenCombis({1, . . . , n}, ntarg,maxtarg)// the target combinations
Cmoda ← GenArrangs(Ω, ntarg ,maxmoda)// the modality arrangements
if Aversus 6= ∅// there are pathological basins to shrink
Btherap ← ComputeTherapeuticBullets(fpatho, S, Ctarg, Cmoda,maxk,
δ, sync,Aphysio, Apatho, Aversus)// therapeutic bullets
end if
return S,Aphysio, Apatho, Aversus, Ctarg, Cmoda, Btherap
end function
Size(container) returns the number of items in container.
GenSpace(Ω, n) returns the n-dimensional state space of the vectors made of n
values from Ω, as a matrix of one state vector per row.
GenArrangs(Ω, n,maxarrang) returns maxarrang arrangements with repetition
made of n elements from Ω, as a matrix of one arrangement per row. If
maxarrang exceeds its maximal possible value then it is automatically decreased
to its maximal possible value.
GenCombis(Ω, n,maxcombi) returns maxcombi combinations without repetition
made of n elements from Ω, as a matrix of one combination per row. Ifmaxcombi
exceeds its maximal possible value then it is automatically decreased to its max-
imal possible value.
As explained later, the function ComputeAttractorSet can use an already com-
puted attractor set, namely the reference set, to name the attractors.
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Aphysio is computed without bullet (b ← ∅), without reference set (Aref ← ∅)
and with the physiological setting (setting ← 0).
Apatho is computed without bullet (b ← ∅), with a reference set (Aref ←
Aphysio) and with the pathological setting (setting ← 1).
Aversus is not a true attractor set but the set containing the pathological at-
tractors: Aversus ⊂ Apatho. Apatho can contains physiological attractors if the
pathological variant exhibits some of them. However, Aversus only contains the
pathological attractors.
Therapeutic bullets are computed only if there are pathological basins to shrink,
namely only if Aversus 6= ∅.
Note that target combinations are combinations of positions in the state vec-
tor: targets are identified by their position in the state vector, not by their name.
function fphysio(x)
// update the state vector of the physiological variant
y[1]← fphysio[1](x)// update x1 with fphysio,1
...
y[n]← fphysio[n](x)// update xn with fphysio,n
return y// the updated state vector
end function
function fpatho(x)
// update the state vector of the pathological variant
y[1]← fpatho[1](x)// update x1 with fpatho,1
...
y[n]← fpatho[n](x)// update xn with fpatho,n
return y// the updated state vector
end function
function ComputeAttractor(f, x0, b,maxk, sync)
// from x0, reach an attractor a
select sync
case 1// search a cycle
a.States← ReachCycle(f, x0, b)
case 0// search a terminal SCC
for
a.States← GoForward(f,Walk(f, x0 , b,maxk), b)// a candidate
if IsT erminal(a, f, b)// the candidate attractor is a terminal SCC
break// then it is an asynchronous attractor
end if
end for
end select
return a
end function
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If ComputeAttractor(f, x0, b,maxk, sync) is run with sync = 0 (i.e. asyn-
chronous case) then ensure that maxk is big enough for random walks to reach
attractors with high probability. Ifmaxk is too small and if there is no attractor
near x0, then this function will run indefinitely since it loops until an attractor
is found starting from x0. The default value of maxk should be 10 000. It can
be smaller for little networks and should be higher for large networks.
function ComputeAttractorSet(f, S, b,maxk, setting, sync,Aref)
// compute an attractor set A, namely Aphysio, Apatho or Atest
A← {}
select setting// select the default name for attractors
case 0// physiological setting
name← aphysio
case 1// pathological setting
name← apatho
end select
for i← 1, . . . , Size(S)// browse S
a← ComputeAttractor(f, S[i], b,maxk, sync)
if ∃iA : A[iA] = a// a is already found
A[iA].Basin← A[iA].Basin+ 1// then increase its basin
else// new attractor
a.Basin← 1// then begin its basin
A← A ∪ {a}// and add it to the attractor set
end if
end for
for i← 1, . . . , Size(A)// browse A
A[i].Basin← 100 ·A[i].Basin/Size(S)// translate basins to % of S
end for
return SetNames(A, name,Aref)// return named attractors, see later
end function
function ComputeTherapeuticBullets(fpatho, S, Ctarg, Cmoda,maxk, δ, sync,
Aphysio, Apatho, Aversus)
// compute a set Btherap of therapeutic bullets
Btherap ← {}
b.Gain[1]← Sum(GetCover(Aphysio, Apatho))//
⋃
Bphysio,i in Spatho
for i1 ← 1, . . . , Size(Ctarg)// browse the target combinations to test
for i2 ← 1, . . . , Size(CModa)// browse the modality arrangements to test
b.T arg ← Ctarg[i1]// the target combination to test
b.Moda← CModa[i2]// the modality arrangement to test
Atest ← ComputeAttractorSet(fpatho, S, b,maxk, 1, sync,Aphysio)
b.Gain[2]← Sum(GetCover(Aphysio, Atest))//
⋃
Bphysio,i in Stest
if IsTherapeutic(b, Atest, Aversus, δ)// b is therapeutic
b.Cover ← GetCover(Aphysio ∪ Aversus, Atest)// basins in Stest
Btherap ← Btherap ∪ {b}// add b to the set of therapeutic bullets
end if
end for
end for
return Btherap
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end function
Sum(container) returns the sum of the items in container.
function GetCover(A1, A2)
// get the size of the B1,i in S2, in % of S2
cover← ()
for i1 ← 1, . . . , Size(A1)// browse the attractors of A1
if ∃i2 : A2[i2] = A1[i1]// A1[i1] also in A2
cover← Append(cover, A2[i2].Basin)// get the size of B1,i1 in S2
else// A1[i1] not in A2
cover← Append(cover, 0)// then B1,i1 is empty in S2
end if
end for
return cover
end function
Append(container, item) returns container with item added to it.
function GetV ersus(Apatho)
// get the pathological attractors
Aversus ← {}// the set of the pathological attractors
for i← 1, . . . , Size(Apatho)// browse the attractors of Apatho
if IsSubString(Apatho[i].Name, patho)// not a physiological attractor
Aversus ← Aversus ∪ {Apatho[i]}// then add it to Aversus
end if
end for
return Aversus
end function
IsSubString(s1, s2) returns true if s2 is a substring of s1.
Remember that Aversus is not a true attractor set but the set containing the
pathological attractors: Aversus ⊂ Apatho.
function GoForward(f, x0 , b)
// compute the forward reachable set fwd of x0 (asynchronous only)
fwd← {x0}// fwd contains x0 itself
stack← (x0)// the stack of the states to check, see below
for
x← stack[Size(stack)]// get the last stack element
stack ← stack[1, . . . , Size(stack)− 1]// remove the last stack element
y ← f(x)// prepare all the updated xi
for i← 1, . . . , Size(y)// browse the updated xi
z ← x// copy x to preserve its original value
z[i]← y[i]// update only one xi
z ← Shoot(z, b)// apply the bullet
if z /∈ fwd// new state
fwd← fwd ∪ {z}// then add it to fwd
stack ← Append(stack, z)// and add it to the states to check
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end if
end for
if Size(stack) = 0// no new states to visit
break// so the complete fwd is obtained
end if
end for
return fwd
end function
stack is the stack of the visited states for which the possible successors are not
yet computed. Once this stack empty, all the visitable states starting from x0
are found, that is the complete forward reachable set of x0 is obtained.
function IsT erminal(a, f, b)
// check if a candidate attractor a is a terminal SCC (asynchronous only)
for i← 1, . . . , Size(a.States)// browse the states of a
if GoForward(f, a.States[i], b) 6= a.States// fwdi 6= a
return false// then not a terminal SCC
end if
end for
return true// assumed to be a terminal SCC until proven otherwise
end function
function IsTherapeutic(b, Atest, Aversus, δ)
// check if a bullet b is therapeutic
if b.Gain[2]− b.Gain[1] ≥ δ// maybe therapeutic
for i← 1, . . . , Size(Atest)// browse the attractors of Atest
if IsSubString(Atest[i].Name, patho) ∧ Atest[i] /∈ Aversus
return false// because of a de novo attractor
end if
end for
return true// assumed to be therapeutic until proven otherwise
else
return false// below the therapeutic threshold
end if
end function
function ReachCycle(f, x0, b)
// compute the cycle reachable from x0 (synchronous only)
cycle← (x0)// begin the trajectory
x← x0
for
x← Shoot(f(x), b)// update and apply the bullet
if ∃i : cycle[i] = x// cycle found in the trajectory
cycle← cycle[i, . . . , Size(cycle)]// then extract the cycle
break// mission completed
else// cycle not yet reached
cycle← Append(cycle, x)// then pursue the trajectory
end if
end for
33
return cycle
end function
function SetNames(A, name,Aref)
// name the attractors of A according to Aref , default to name
y ← A// copy A to return a copy
k← 1// initiate the default name numbering
for i← 1, . . . , Size(A)// browse the attractors of A
if ∃iref : Aref [iref ] = A[i]// A[i] found in Aref
y[i].Name← Aref [iref ].Name// then get its name in Aref
else// A[i] not in Aref
y[i].Name← CatStrings(name, T oString(k))// default name
k ← k + 1// and increment the default name numbering
end if
end for
return y
end function
CatStrings(s1, s2) returns the concatenation of s1 and s2.
ToString(item) returns the string corresponding to item.
This function names the attractors of A according to a reference set Aref . If an
attractor of A also belongs to Aref then its name in Aref is used, otherwise the
default name numbered with k is used.
function Shoot(x, b)
// apply a bullet on a state
y ← x// copy x to return a copy
for i← 1, . . . , Size(b.T arg)// browse the targets
y[b.T arg[i]]← b.Moda[i]// apply the corresponding modality
end for
return y
end function
Remember that targets are identified by their position in the state vector, not
by their name.
function Walk(f, x0, b,maxk)
// perform a random walk of maxk steps from x0 (asynchronous only)
x← x0// start the walk
for k ← 1, . . . ,maxk// for maxk steps
y ← f(x)// prepare all the updated xi
i← RandInt(1, Size(x))// randomly choose one xi
x[i]← y[i]// then update the chosen xi
x← Shoot(x, b)// and apply the bullet
end for
return x
end function
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RandInt(a, b) returns a randomly selected integer in [[a; b]] according to a uni-
form distribution.
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8 Appendix 4: case study equations
Below are the 27 Boolean equations of the case study derived from the model of
bladder tumorigenesis by Elisabeth Remy and colleagues [16]. These equations
are also available in text format in the supporting file bladder_equations.txt.
A network-based representation is shown in Figure 2 page 10.
AKT = PI3K
ATMlvl1 = DNAdamage ∧ ¬E2F1lvl1 ∧ ¬E2F1lvl2
ATMlvl2 = (E2F1lvl1 ∨E2F1lvl2) ∧DNAdamage
CDC25A = ¬CHEK1/2lvl1 ∧ ¬CHEK1/2lvl2 ∧ ¬RBL2
∧(E2F1lvl1 ∨E2F1lvl2 ∨E2F3lvl1 ∨E2F3lvl2)
CHEK1/2lvl1 = (ATMlvl1 ∨ATMlvl2) ∧ ¬E2F1lvl1 ∧ ¬E2F1lvl2
CHEK1/2lvl2 = (E2F1lvl1 ∨E2F1lvl2) ∧ (ATMlvl1 ∨ ATMlvl2)
CyclinA = ¬RBL2 ∧ ¬p21CIP ∧ CDC25A
∧(E2F1lvl1 ∨E2F1lvl2 ∨E2F3lvl1 ∨E2F3lvl2)
CyclinD1 = (RAS ∨AKT ) ∧ ¬p16INK4a ∧ ¬p21CIP
CyclinE1 = ¬RBL2 ∧ ¬p21CIP ∧ CDC25A
∧(E2F1lvl1 ∨E2F1lvl2 ∨E2F3lvl1 ∨E2F3lvl2)
E2F1lvl1 = ¬RB1 ∧ ¬RBL2 ∧ ((CHEK1/2lvl2 ∧ATMlvl2 ∧ ¬RAS ∧E2F3lvl1)
∨((¬CHEK1/2lvl2 ∨ ¬ATMlvl2) ∧ (RAS ∨E2F3lvl1 ∨ E2F3lvl2)))
E2F1lvl2 = ¬RBL2 ∧ ¬RB1 ∧ATMlvl2 ∧ CHEK1/2lvl2 ∧ (RAS ∨E2F3lvl2)
E2F3lvl1 = ¬RB1 ∧ ¬CHEK1/2lvl2 ∧RAS
E2F3lvl2 = ¬RB1 ∧ CHEK1/2lvl2 ∧RAS
EGFR = (EGFRstimulus ∨ SPRY ) ∧ ¬FGFR3 ∧ ¬GRB2
FGFR3 = ¬EGFR ∧ FGFR3stimulus ∧ ¬GRB2
GRB2 = (FGFR3 ∧ ¬GRB2 ∧ ¬SPRY ) ∨ EGFR
MDM2 = (TP53 ∨AKT ) ∧ ¬p14ARF ∧ ¬ATMlvl1 ∧ ¬ATMlvl2 ∧ ¬RB1
p14ARF = E2F1lvl1 ∨E2F1lvl2
p16INK4a = GrowthInhibitors ∧ ¬RB1
p21CIP = ¬CyclinE1 ∧ (GrowthInhibitors ∨ TP53) ∧ ¬AKT
PI3K = GRB2 ∧RAS ∧ ¬PTEN
PTEN = TP53
RAS = EGFR ∨ FGFR3 ∨GRB2
RB1 = ¬CyclinD1 ∧ ¬CyclinE1 ∧ ¬p16INK4a ∧ ¬CyclinA
RBL2 = ¬CyclinD1 ∧ ¬CyclinE1
SPRY = RAS
TP53 = ¬MDM2 ∧ (E2F1lvl2 ∨ ((ATMlvl1 ∨ ATMlvl2)
∧(CHEK1/2lvl1 ∨ CHEK1/2lvl2)))
The four input parameters areEGFRstimulus, FGFR3stimulus,GrowthInhibitors
and DNAdamage. The three outputs are evaluated from the returned attrac-
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tors once the run terminated according to their respective equation:
Proliferation = CyclinE1 ∨ CyclinA
GrowthArrest = p21CIP ∨RB1 ∨ RBL2
Apoptosis = TP53 ∨ E2F1lvl2
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